Company International Stem Cell Corporation

Equities

ISCO

US4603782016

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sales per region

Sector Other Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 10:45:04 2024-04-24 am EDT			5-day change	1st Jan Change
0.065 ^USD	-8.71%		-8.71%	+4.84%

Mar. 28	International Stem Cell Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	International Stem Cell Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

International Stem Cell Corporation is a clinical-stage biotechnology company that is focused on therapeutic and biomedical product development. The Company is primarily a research and development company, for the therapeutic market, which has focused on advancing potential clinical applications of human parthenogenetic stem cells (hpSCs) for the treatment of various diseases of the central nervous system and liver diseases. The Company's products are based on human cell culture and a type of pluripotent stem cells and hpSCs. The Company's subsidiaries include Lifeline Cell Technology, LLC (LCT), which develops, manufactures and commercializes primary human cell research products for the biomedical market; Lifeline Skin Care, Inc. (LSC), which develops, manufactures and markets a category of anti-aging skin care products for anti-aging market, and Cyto Therapeutics Pty. Ltd. (Cyto Therapeutics) performs research and development (R&D) for the therapeutic market.

Number of employees: 29

USD in Million	2022	Weight	2023	Weight	Delta
Biomedical 88.1 %	7	87.2 %	7	88.1 %	-3.72%
Anti-Aging 11.9 %	1	12.8 %	1	11.9 %	-12.01%

USD in Million	2022	Weight	2023	Weight	Delta
United States 84.1 %	7	85.8 %	7	84.1 %	-6.67%
Asia 9.3 %	1	8.4 %	1	9.3 %	+5.22%
Europe 5.1 %	0	4.8 %	0	5.1 %	+0.51%
All Other Regions 1.5 %	0	1.0 %	0	1.5 %	+48.15%

Managers	Title	Age	Since
Andrey Semechkin CEO	Chief Executive Officer	64	08-11-30
Russell Kern DFI	Director of Finance/CFO	38	08-09-30

Members of the board	Title	Age	Since
Russell Kern DFI	Director of Finance/CFO	38	08-09-30
Paul Maier BRD	Director/Board Member	76	07-06-30
Andrey Semechkin CEO	Chief Executive Officer	64	08-11-30
Donald A. Wright CHM	Chairman	72	07-02-28

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	8,004,389	3,700,522 ( 46.23 %)	0	27.91 %
Stock B	0	5,254,310	0	0

Name	Equities	%	Valuation
Andrey Semechkin 53.30 %	4,266,326	53.30 %	354 105 $
Paul Maier 0.4098 %	32,802	0.4098 %	2 723 $
Donald A. Wright 0.0592 %	4,739	0.0592 %	393 $
Russell Kern 0.000000 %	0	0.000000 %	- $

Name	Equities	%	Valuation
Ar Partners LLC 100.00 %	5,000,000	100.00 %	415 000 $

International Stem Cell Corp.

9745 Businesspark Avenue

92131, San Diego

http://www.internationalstemcell.com

address International Stem Cell Corporation(ISCO)

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
INTERNATIONAL STEM CELL CORPORATION	+4.84%	520K
IQVIA HOLDINGS INC.	+1.12%	43.84B
MODERNA, INC.	+6.77%	41.68B
LONZA GROUP AG	+45.26%	41.25B
CELLTRION, INC.	-11.96%	27.04B
ICON PUBLIC LIMITED COMPANY	+6.01%	25.53B
ALNYLAM PHARMACEUTICALS, INC.	-24.92%	18.18B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.63%	12.29B
MEDPACE HOLDINGS, INC.	+27.16%	12.29B
UNITED THERAPEUTICS CORPORATION	+7.30%	11.15B

Other Biotechnology & Medical Research